Toos Daemen

List of Publications by Year
in descending order

110 papers	6,402 citations	101384 36 h-index	69108 77 g-index
112 all docs	112 docs citations	112 times ranked	9605 citing authors

#	Article	IF	Citations
1	The combined signatures of hypoxia and cellular landscape provides a prognostic and therapeutic biomarker in hepatitis B virusâ€related hepatocellular carcinoma. International Journal of Cancer, 2022, 151, 809-824.	2.3	11
2	First-in-Human Phase I Clinical Trial of an SFV-Based RNA Replicon Cancer Vaccine against HPV-Induced Cancers. Molecular Therapy, 2021, 29, 611-625.	3.7	48
3	Re-polarization of immunosuppressive macrophages to tumor-cytotoxic macrophages by repurposed metabolic drugs. OncoImmunology, 2021, 10, 1898753.	2.1	28
4	Resistance Mechanisms Influencing Oncolytic Virotherapy, a Systematic Analysis. Vaccines, 2021, 9, 1166.	2.1	13
5	A systematic analysis on the clinical safety and efficacy of onco-virotherapy. Molecular Therapy - Oncolytics, 2021, 23, 239-253.	2.0	7
6	GMP manufacturing of Vvax001, a therapeutic anti-HPV vaccine based on recombinant viral particles. European Journal of Pharmaceutical Sciences, 2020, 143, 105096.	1.9	8
7	Therapy-Induced Changes in CXCR4 Expression in Tumor Xenografts Can Be Monitored Noninvasively with N-[11C]Methyl-AMD3465 PET. Molecular Imaging and Biology, 2020, 22, 883-890.	1.3	6
8	Therapeutic Vaccines and Cancer Immunotherapy. Vaccines, 2020, 8, 596.	2.1	6
9	Hepatitis C Virus Proteins Core and NS5A Are Highly Sensitive to Oxidative Stress-Induced Degradation after eIF2Î±/ATF4 Pathway Activation. Viruses, 2020, 12, 425.	1.5	11
10	Alphavirus-based hepatitis C virus therapeutic vaccines: can universal helper epitopes enhance HCV-specific cytotoxic T lymphocyte responses?. , 2019, 7, 251513551987467.	1.4	2
11	SP-0553 Imaging of tumor infiltrating lymphocytes with [18F]FB-IL2 PET. Radiotherapy and Oncology, 2019, 133, S291.	0.3	0
12	Hepatitis C virus core or NS3/4A protein expression preconditions hepatocytes against oxidative stress and endoplasmic reticulum stress. Redox Report, 2019, 24, 17-26.	1.4	15
13	The cellular stress response in hepatitis C virus infection: A balancing act to promote viral persistence and host cell survival. Virus Research, 2019, 263, 1-8.	1.1	15
14	An alphavirus-based therapeutic cancer vaccine: from design to clinical trial. Cancer Immunology, Immunotherapy, 2019, 68, 849-859.	2.0	19
15	Antigen-specific active immunotherapy for ovarian cancer. The Cochrane Library, 2018, 9, CD007287.	1.5	11
16	Changes in (risk) behavior and HPV knowledge among Dutch girls eligible for HPV vaccination: an observational cohort study. BMC Public Health, 2018, 18, 837.	1.2	6
17	Potent therapeutic efficacy of an alphavirus replicon DNA vaccine expressing human papilloma virus E6 and E7 antigens. OncoImmunology, 2018, 7, e1487913.	2.1	36
18	TLR9-Mediated Conditioning of Liver Environment Is Essential for Successful Intrahepatic Immunotherapy and Effective Memory Recall. Molecular Therapy, 2017, 25, 2289-2298.	3.7	8

#	Article	IF	Citations
19	CD103+ tumor-infiltrating lymphocytes are tumor-reactive intraepithelial CD8+ T cells associated with prognostic benefit and therapy response in cervical cancer. OncoImmunology, 2017, 6, e1338230.	2.1	116
20	Noninvasive monitoring of cancer therapy induced activated T cells using [¹⁸F]FB-IL-2 PET imaging. OncoImmunology, 2017, 6, e1248014.	2.1	51
21	Cost-Effectiveness of Additional Human Papillomavirus Vaccination Programmes, in The Netherlands. Value in Health, 2017, 20, A443.	0.1	0
22	Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell Response. Clinical Cancer Research, 2016, 22, 2342-2350.	3.2	132
23	Treatment Regimen, Surgical Outcome, and T-cell Differentiation Influence Prognostic Benefit of Tumor-Infiltrating Lymphocytes in High-Grade Serous Ovarian Cancer. Clinical Cancer Research, 2016, 22, 714-724.	3.2	51
24	CD103+ intraepithelial T cells in high-grade serous ovarian cancer are phenotypically diverse TCRÎ±Î²+ CD8Î±Î²+ T cells that can be targeted for cancer immunotherapy. Oncotarget, 2016, 7, 75130-75144.	0.8	64
25	Abstract A108: CD103+ intraepithelial T cells in high-grade serous ovarian cancer are phenotypically diverse TCRÎ±Î²+ CD8Î±Î²+ T cells that can be targeted for cancer immunotherapy. , 2016, , .		0
26	Epitope Prediction Assays Combined with Validation Assays Strongly Narrows down Putative Cytotoxic T Lymphocyte Epitopes. Vaccines, 2015, 3, 203-220.	2.1	29
27	Tattoo Delivery of a Semliki Forest Virus-Based Vaccine Encoding Human Papillomavirus E6 and E7. Vaccines, 2015, 3, 221-238.	2.1	14
28	Antigen design enhances the immunogenicity of Semliki Forest virus-based therapeutic human papillomavirus vaccines. Gene Therapy, 2015, 22, 560-567.	2.3	17
29	Prediction model for regional or distant recurrence in endometrial cancer based on classical pathological and immunological parameters. British Journal of Cancer, 2015, 113, 786-793.	2.9	20
30	Sunitinib depletes myeloid-derived suppressor cells and synergizes with a cancer vaccine to enhance antigen-specific immune responses and tumor eradication. OncoImmunology, 2015, 4, e989764.	2.1	95
31	Strategies to Target Tumor Immunosuppression. , 2015, , 73-86.		0
32	Myeloid derived suppressor cellsâ€”An overview of combat strategies to increase immunotherapy efficacy. OncoImmunology, 2015, 4, e954829.	2.1	219
33	The costâ€“effectiveness of HPV vaccination in addition to screening: a Dutch perspective. Expert Review of Vaccines, 2015, 14, 589-604.	2.0	11
34	A rationally designed combined treatment with an alphavirus-based cancer vaccine, sunitinib and low-dose tumor irradiation completely blocks tumor development. OncoImmunology, 2015, 4, e1029699.	2.1	23
35	A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer. Oncotarget, 2015, 6, 32228-32243.	0.8	58
36	Elevated serum CXCL16 is an independent predictor of poor survival in ovarian cancer and may reflect pro-metastatic ADAM protease activity. British Journal of Cancer, 2014, 110, 1535-1544.	2.9	30

#	Article	IF	Citations
37	Alphavirus-based Vaccines Encoding Nonstructural Proteins of Hepatitis C Virus Induce Robust and Protective T-cell Responses. Molecular Therapy, 2014, 22, 881-890.	3.7	30
38	Therapeutic immunization and local lowâ€dose tumor irradiation, a reinforcing combination. International Journal of Cancer, 2014, 134, 859-872.	2.3	38
39	Interleukin-6 receptor and its ligand interleukin-6 are opposite markers for survival and infiltration with mature myeloid cells in ovarian cancer. OncoImmunology, 2014, 3, e962397.	2.1	27
40	Equity in human papilloma virus vaccination uptake?: sexual behaviour, knowledge and demographics in a cross-sectional study in (un)vaccinated girls in the Netherlands. BMC Public Health, 2014, 14, 288.	1.2	17
41	Antigen-specific active immunotherapy for ovarian cancer. The Cochrane Library, 2014, , CD007287.	1.5	19
42	HPV-Specific Immunotherapy: Key Role for Immunomodulators. Anti-Cancer Agents in Medicinal Chemistry, 2014, 14, 265-279.	0.9	12
43	Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands. BMC Infectious Diseases, 2013, 13, 75.	1.3	26
44	Costâ€"effectiveness of the prophylactic HPV vaccine: An application to the Netherlands taking non-cervical cancers and cross-protection into account. Vaccine, 2013, 31, 3922-3927.	1.7	16
45	Antigen-specific Immunotherapy in Ovarian Cancer and p53 as Tumor Antigen. Current Pharmaceutical Design, 2012, 18, 3804-3811.	0.9	12
46	Therapeutic vaccination against chronic hepatitis C virus infection. Antiviral Research, 2012, 96, 36-50.	1.9	26
47	On Discounting of Health Gains from Human Papillomavirus Vaccination: Effects of Different Approaches. Value in Health, 2012, 15, 562-567.	0.1	27
48	PCN13 Analysis of the Impact of Prophylactic Vaccination Against Human Papillomavirus Infection Using a Dynamic-Modelling Approach. Value in Health, 2012, 15, A411.	0.1	0
49	Potentiation of a p53â€SLP vaccine by cyclophosphamide in ovarian cancer: A singleâ€arm phase II study. International Journal of Cancer, 2012, 131, E670-80.	2.3	81
50	Longâ€term clinical and immunological effects of p53â€SLPÂ® vaccine in patients with ovarian cancer. International Journal of Cancer, 2012, 130, 105-112.	2.3	49
51	The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. British Journal of Cancer, 2011, 105, 93-103.	2.9	1,045
52	Heterologous Prime-Boost Immunizations with a Virosomal and an Alphavirus Replicon Vaccine. Molecular Pharmaceutics, 2011, 8, 65-77.	2.3	18
53	Role of regulatory T-cells in immunization strategies involving a recombinant alphavirus vector system. Antiviral Therapy, 2011, 16, 207-218.	0.6	16
54	Tumor-infiltrating Cytotoxic T Lymphocytes as Independent Prognostic Factor in Epithelial Ovarian Cancer With Wilms Tumor Protein 1 Overexpression. Journal of Immunotherapy, 2011, 34, 516-523.	1.2	25

#	Article	IF	Citations
55	Vaccine-based clinical trials in ovarian cancer. Expert Review of Vaccines, 2011, 10, 775-784.	2.0	13
56	Immunological and Clinical Effects of Vaccines Targeting p53-Overexpressing Malignancies. Journal of Biomedicine and Biotechnology, 2011, 2011, 1-11.	3.0	31
57	Until Which Age Should Women Be Vaccinated Against HPV Infection? Recommendation Based on Cost-effectiveness Analyses. Journal of Infectious Diseases, 2011, 204, 377-384.	1.9	52
58	From Tumor Immunosuppression to Eradication: Targeting Homing and Activity of Immune Effector Cells to Tumors. Clinical and Developmental Immunology, 2011, 2011, 1-15.	3.3	123
59	Identification of genes and pathways associated with cytotoxic T lymphocyte infiltration of serous ovarian cancer. British Journal of Cancer, 2010, 103, 685-692.	2.9	43
60	Role of T cell competition in the induction of cytotoxic T lymphocyte activity during viral vector-based immunization regimens. Vaccine, 2010, 28, 4275-4282.	1.7	10
61	Down-regulation of proteasomal subunit MB1 is an independent predictor of improved survival in ovarian cancer. Gynecologic Oncology, 2009, 113, 256-263.	0.6	21
62	Immunization with a P53 synthetic long peptide vaccine induces P53â€specific immune responses in ovarian cancer patients, a phase II trial. International Journal of Cancer, 2009, 125, 2104-2113.	2.3	123
63	Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Cancer Immunology, Immunotherapy, 2009, 58, 449-459.	2.0	347
64	Cost-effectiveness of prophylactic vaccination against human papillomavirus 16/18 for the prevention of cervical cancer: Adaptation of an existing cohort model to the situation in the Netherlands. Vaccine, 2009, 27, 4776-4783.	1.7	28
65	Viral vector-based prime-boost immunization regimens: a possible involvement of T-cell competition. Gene Therapy, 2008, 15, 393-403.	2.3	19
66	Survival of ovarian cancer patients overexpressing the tumour antigen p53 is diminished in case of MHC class I down-regulation. Gynecologic Oncology, 2008, 110, 365-373.	0.6	32
67	Serum Cytokine Profiling as a Diagnostic and Prognostic Tool in Ovarian Cancer: A Potential Role for Interleukin 7. Clinical Cancer Research, 2007, 13, 2385-2391.	3.2	99
68	P53-specific T cell responses in patients with malignant and benign ovarian tumors: Implications for p53 based immunotherapy. International Journal of Cancer, 2007, 121, 606-614.	2.3	34
69	A comparative study on the immunotherapeutic efficacy of recombinant Semliki Forest virus and adenovirus vector systems in a murine model for cervical cancer. Gene Therapy, 2007, 14, 1695-1704.	2.3	27
70	Frequencies and role of regulatory T cells in patients with (pre)malignant cervical neoplasia. Clinical and Experimental Immunology, 2007, 150, 199-209.	1.1	76
71	Recombinant alphaviruses as vectors for anti-tumour and anti-microbial immunotherapy. Journal of Clinical Virology, 2006, 35, 233-243.	1.6	31
72	Enhancement of human papilloma virus type 16 E7 specific T cell responses by local invasive procedures in patients with (pre)malignant cervical neoplasia. International Journal of Cancer, 2006, 118, 2529-2537.	2.3	17

#	Article	IF	Citations
73	A Virosomal Immunization Strategy against Cervical Cancer and Pre-Malignant Cervical Disease. Antiviral Therapy, 2006, 11, 717-728.	0.6	20
74	Virosomes for antigen and DNA delivery. Advanced Drug Delivery Reviews, 2005, 57, 451-463.	6.6	94
75	Induction of human papilloma virus E6/E7-specific cytotoxic T-lymphocyte activity in immune-tolerant, E6/E7-transgenic mice. Gene Therapy, 2005, 12, 1410-1414.	2.3	39
76	Immunologic aspect of ovarian cancer and p53 as tumor antigen. Journal of Translational Medicine, 2005, 3, 34.	1.8	31
77	Induction of cytotoxic T lymphocyte activity by immunization with recombinant Semliki Forest virus: indications for cross-priming. Vaccine, 2004, 22, 1104-1113.	1.7	30
78	Superior therapeutic efficacy of alphavirus-mediated immunization against human papilloma virus type 16 antigens in a murine tumour model: effects of the route of immunization. Antiviral Therapy, 2004, 9, 733-42.	0.6	28
79	Superior Therapeutic Efficacy of Alphavirus-Mediated Immunization against Human Papilloma Virus Type 16 Antigens in a Murine Tumour Model: Effects of the Route of Immunization. Antiviral Therapy, 2004, 9, 733-742.	0.6	53
80	Eradication of established HPV16-transformed tumours after immunisation with recombinant Semliki Forest virus expressing a fusion protein of E6 and E7. Vaccine, 2003, 21, 1082-1088.	1.7	63
81	Influenza Virosomes in Vaccine Development. Methods in Enzymology, 2003, 373, 74-91.	0.4	42
82	Immunization strategy against cervical cancer involving an alphavirus vector expressing high levels of a stable fusion protein of human papillomavirus 16 E6 and E7. Gene Therapy, 2002, 9, 85-94.	2.3	60
83	VIROSOMES IN VACCINE DEVELOPMENT: INDUCTION OF CYTOTOXIC T LYMPHOCYTE ACTIVITY WITH VIROSOME-ENCAPSULATED PROTEIN ANTIGENS. Journal of Liposome Research, 2002, 12, 155-163.	1.5	27
84	Virosome-mediated delivery of protein antigens to dendritic cells. Vaccine, 2002, 20, 2287-2295.	1.7	124
85	A potential role of macrophage activation in the treatment of cancer. Critical Reviews in Oncology/Hematology, 2002, 44, 143-161.	2.0	291
86	Delivery of Protein Antigens to the Immune System by Fusion-Active Virosomes: A Comparison with Liposomes and ISCOMs. Bioscience Reports, 2002, 22, 323-338.	1.1	72
87	Activation of peritoneal cells upon in vivo transfection with a recombinant alphavirus expressing GM-CSF. Gene Therapy, 2001, 8, 300-307.	2.3	28
88	Expression of cyclooxygenase-2 and inducible nitric oxide synthase in human ovarian tumors and tumor-associated macrophages. Cancer Research, 2001, 61, 7305-9.	0.4	146
89	Genetic immunization against cervical carcinoma: induction of cytotoxic T lymphocyte activity with a recombinant alphavirus vector expressing human papillomavirus type 16 E6 and E7. Gene Therapy, 2000, 7, 1859-1866.	2.3	53
90	Virosomes as an Antigen Delivery System. Journal of Liposome Research, 2000, 10, 329-338.	1.5	17

#	Article	IF	Citations
91	Toxicity of doxorubicin entrapped within long-circulating liposomes. Journal of Controlled Release, 1997, 44, 1-9.	4.8	55
92	Liposomes: vehicles for the targeted and controlled delivery of peptides and proteins. Journal of Controlled Release, 1997, 46, 165-175.	4.8	28
93	Modulation of pharmacokinetic behavior of liposomes. Advanced Drug Delivery Reviews, 1997, 24, 179-191.	6.6	33
94	Different intrahepatic distribution of phosphatidylglycerol and phosphatidylserine liposomes in the rat. Hepatology, 1997, 26, 416-423.	3.6	65
95	Tumoricidal response of liver macrophages isolated from rats bearing liver metastases of colon adenocarcinoma. Journal of Leukocyte Biology, 1995, 57, 617-623.	1.5	22
96	Liposomal doxorubicin-induced toxicity: Depletion and impairment of phagocytic activity of liver macrophages. International Journal of Cancer, 1995, 61, 716-721.	2.3	132
97	Antitumor reactivity induced by liposomal MTP-PE in a liver metastasis model of colon cancer in the rat. Clinical and Experimental Metastasis, 1995, 13, 328-36.	1.7	12
98	Opportunities in targeted drug delivery to Kupffer cells: delivery of immunomodulators to Kupffer cells-activation of tumoricidal properties. Advanced Drug Delivery Reviews, 1995, 17, 21-30.	6.6	12
99	Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Advanced Drug Delivery Reviews, 1995, 17, 31-48.	6.6	788
100	Heterogeneity in secretory responses of rat liver macrophages of different size. Liver, 1995, 15, 313-319.	0.1	17
101	Proliferation of rat liver macrophagesin vitro: Influence of hemopoietic growth factors. Hepatology, 1994, 19, 666-674.	3.6	20
102	Liver metastasis model of colon cancer in the rat: immunohistochemical characterization. Invasion & Metastasis, 1993, 13, 102-12.	0.5	36
103	Activation of Kupffer cell tumoricidal activity by immunomodulators encapsulated in liposomes. Research in Immunology, 1992, 143, 211-214.	0.9	17
104	Therapy of Murine Liver Metastases by Administration of MDP Encapsulated in Liposomes. Selective Cancer Therapeutics, 1990, 6, 63-71.	0.5	26
105	Endocytic and Tumoricidal Heterogeneity of Rat Liver Macrophage Populations. Selective Cancer Therapeutics, 1989, 5, 157-167.	0.5	21
106	Differential effects of liposome-incorporation on liver macrophage activating potencies of rough lipopolysaccharide, lipid A, and muramyl dipeptide. Differences in susceptibility to lysosomal enzymes. Journal of Immunology, 1989, 142, 2469-74.	0.4	12
107	Liposomes in chemo- and immunotherapy of cancer. Lipids, 1987, 22, 891-896.	0.7	11
108	In vitro activation of rat liver macrophages to tumoricidal activity by free or liposome-encapsulated muramyl dipeptide. Cancer Research, 1986, 46, 4330-5.	0.4	69

#	Article	IF	Citations
109	T-cell maturation in the human thymus and tonsil: Peanut agglutinin binding T lymphocytes in thymus and tonsil differ in maturation stage. Clinical Immunology and Immunopathology, 1983, 29, 271-281.	2.1	14
110	Immunization strategy against cervical cancer involving an alphavirus vector expressing high levels of a stable fusion protein of human papillomavirus 16 E6 and E7. , 0, .		2